Talphera, Inc. - Q3 2026 Financial Results Conference Call - TALPHERA INC

Financial Performance:

• Cash balance as of September 30, 2026: $14.2 million.
• Combined R&D and SG&A operating expenses (excluding stock-based compensation) for Q3 2026: $3.8 million, a $0.5 million increase year-over-year driven by NIAID development costs and pre-launch commercial preparation.
• Remaining capital: Two conditional financing tranches totaling approximately $16 million, expected to close around top-line data release and study completion.
• Capital runway management: Current cash plus conditional tranches sufficient to reach potential PMA approval in 2027; filing a Form S-3 Shelf Registration Statement to replace the expiring November 30, 2026 document.
• No revenue recognized; company remains in pre-commercial development phase.

Guidance and Future Outlook:

• Regulatory Strategy: Submitted an FDA Sprint Meeting request to close the NIAID CRRT registrational study early by December 31, 2026, utilizing current enrollment (75%+ of target) with >80% statistical power, rather than completing the originally planned 70 patients.
• Timing Expectations: FDA feedback anticipated by year-end 2026; top-line data expected 4–6 weeks post-enrollment closure; potential PMA filing and approval targeted for 2027.
• Market Sizing: Increased estimate for peak annual U.S. sales of NIAID in CRRT to exceed $200 million based on updated physician feedback and quantitative/qualitative research.
• Long-term Goal: Maintain study integrity while accelerating time to market; anticipate potential product availability for physicians by end of 2027 if approval is secured promptly under the Breakthrough Devices Program.

Business Segments and Product Lines:

• NIAID (Nefamistat): Investigational methamostat-based regional anticoagulant for extracorporeal circuits during Continuous Renal Replacement Therapy (CRRT).
• Commercial Potential: Unique profile addresses limitations of existing anticoagulants (e.g., citrate); elevated as an alternative in updated KDIGO guidelines.
• Study Progress: Enrollment exceeds 75% of the planned target; recent enrollment has slowed significantly (85-90% drop vs. prior year period) due to unpredictable ICU patient qualification, not protocol issues.
• Secondary Endpoints: High confidence in meeting secondary endpoints (filter lifespan, clotting events) based on comparable historical data from smaller studies and the study's therapeutic targeting approach.

Market and Competitive Landscape:

• Market Trends: Recent New England Journal of Medicine study favors CRRT over intermittent hemodialysis for acute kidney injury patients, potentially expanding the overall CRRT market.
• Competition/Current Standard: Citrate is currently used off-label by >20-30% of CRRT providers; however, citrate studies have faced severe enrollment challenges (e.g., Fresenius, Vantiv/Baxter trials), highlighting the difficulty of translating clinical trial enrollment to real-world adoption.
• Competitive Advantage: NIAID's position as a distinct alternative where citrate cannot be used, supported by 40+ years of global safety data.

Risks and Challenges:

• Enrollment Volatility: Critically ill ICU patient enrollment is highly unpredictable and erratic; recent slow enrollment was not attributable to specific protocol amendments or site fatigue.
• Regulatory Uncertainty: The Sprint Meeting request outcome is not guaranteed; potential scenarios include rejection (requiring return to original 70-patient target), approval, or a middle-ground requirement for additional data.
• Market vs. Trial Disconnect: Historical enrollment difficulties in clinical trials (citrate examples) do not necessarily correlate with real-world market penetration success, creating valuation risk for sales estimates.
• Cash Runway: Dependency on achieving conditional financing tranches to extend runway past current reserves.

Management Commentary and Tone:

• Tone: Cautiously optimistic and proactive; management emphasizes control over timelines despite enrollment headwinds.
• Confidence: Strong belief in the statistical power (>80%) of the current dataset and the commercial potential of NIAID.
• Strategic Stance: Willing to adjust regulatory path to avoid unnecessary delays, leveraging Breakthrough Device designation for a 6-month review clock.
• Site Relations: Investigator enthusiasm remains high with no observed site fatigue; physicians are eager for product access.

Analyst Questions and Answers:

• Enrollment Slowdown: Management attributes the 85-90% enrollment drop to unpredictable patient exclusion criteria and consent issues over a 2-3 month window, not protocol failures.
• Statistical Power: CMO confirmed the study retains >80% power for primary endpoints with current enrollment; secondary endpoints supported by historical precedent studies with similar sample sizes (N=55-60).
• FDA Feedback Scenarios: Q&A revealed three potential outcomes: outright rejection (continue to 70 patients), immediate approval to submit PMA, or a hybrid approach allowing PMA filing while keeping the study open for supplemental data.
• Sales Estimate Justification: CFO clarified that clinical trial enrollment rates cannot be used to model real-world sales due to distinct constraints (protocols, consents); cited citrate's 25-30% market share despite failed trial enrollments as evidence of this disconnect.
• Safety Data: FDA does not require a fixed patient count for safety due to NIAID's 40-year global track record and well-characterized safety profile; non-US safety data will be submitted to supplement the filing.
• FDA Timing: Sprint meetings are time-bound (45-day clock); feedback expected before December 31, 2026.

Other Key Points:

• Precedent: Cited three specific CRRT anticoagulant studies (Vantiv/Baxter, Fresenius, and others) that faced enrollment hurdles and successfully engaged in regulatory renegotiation to achieve approval.
• Therapeutic Window: Differentiator is the study's ability to target a specific therapeutic window for blood thinning, unlike previous historical studies which used non-titrated doses.
• Investor Event: A dedicated investor and analyst event is scheduled for Q1 2027 to discuss NIAID's commercial opportunity in greater detail.